[1-4, 7, 8, 12, 20, 21] Mortality AF Mortality SR Mortality AF Su

[1-4, 7, 8, 12, 20, 21] Mortality AF Mortality SR Mortality AF Survival AF Survival AF + SR (paroxysmal) Mortality AF Mortality SR Mortality AF Mortality SR Wizemann et al.[1] (2010) DOPPS study 17513 (12.5% AF prevalence rate) All age: HR 1.16 (95% CI 1.08–1.25, P < 0.001) Age < 65: HR 1.29 (95% CI 0.45–3.68, P = 0.63) Age 66–75: HR 1.35 (95% CI 0.69–2.63, P = 0.39) Age > 75: HR 2.17 (95% CI 1.04–4.53, P = 0.04)

Chan et al.[21] (2009) n = 41 425 Prevalence of drug use 8.3% warfarin 10% clopidogrel 30.4% aspirin Prevalence of AF by drug use 8.3% warfarin 10% clopidogrel 30.4% aspirin 8% two or three drugs Treatment type Warfarin Aspirin Clopidogrel Aspirin and warfarin Period 5 years Mortality CCR antagonist Staurosporine supplier by different drug therapy (unadjusted) HR 1.73 (95% CI 1.62–1.85) HR 1.17 (95% CI 1.12–1.22) HR 1.50 (95% CI 1.39–1.62) HR 1.11 (95% CI 1.03–1.86) Olesen et al.[11] (2012) n = 901 19.8% warfarin 17% aspirin 5% warfarin and aspirin 3114 (No.

of person-years) 914 (No. of events) 29.35 event rate/100 person-years (95% CI 27.51–31.32) Warfarin is recommended in general population with AF who has a CHADS2 (C = Congestive Heart failure, H = Hypertension, A = Age ≥ 75 year, D = Diabetes Melitus, S2 prior stroke or Transient Ischemic attack or Thromboembolism) score of ≥2. However, Wizemann et al. study showed that warfarin use in HD was associated with a significantly higher mortality rate, particularly in elderly patients (>75 years).[1] On the contrary, a large (1671 patients, 30% warfarin use) retrospective study showed that warfarin use did not associate with statistically significant increases in all-cause mortality or before hospitalization.[23] Chan et al. in his another study showed that warfarin use was associated with significantly higher mortality and adverse events compared with non-use. However, only 8.3% of the 41 425 patients received warfarin in this study, which reduces

the validity of the data.[21] Warfarin use clearly did not show consistent benefit in mortality in haemodialysis patients with atrial fibrillation. Haemodialysis patients with AF are at increased risk of both thromboembolic complications and bleeding (Table 4).[24-27] In the US Renal Data System (USRDS) 2006 report, patients with end-stage renal disease (ESRD) and AF had a 1.6-fold higher rate of stroke than those without AF. There is very high incidence of stroke in CKD that increases with decreasing estimated glomerular filtration rate (eGFR) irrespective of AF. The stroke incidence in USRDS 2005 report was 15.1% in HD patients compared with 9.6% in patients with CKD and 2.6% in matched patients without CKD.22 In a small HD cohort of 155 patients with AF (12.5% of patients were on warfarin), stroke rate was 4.9 cases/100 patient-years.[10] In this small study, there was no difference in stroke or bleeding between warfarin users and non-users. Interestingly, in Genovesi et al.

Comments are closed.